Table 1.
Baseline Demographics and Disease Characteristics.
| Parameter | Ruxolitinib (N=155) | Placebo (N=154) |
|---|---|---|
| Median age (range) – yr | 66 (43–91) | 70 (40–86) |
| Proportion of male patients – % | 51 | 57 |
| Myelofibrosis subtype – % of patients | ||
| PMF | 45 | 55 |
| PPV-MF | 32 | 31 |
| PET-MF | 23 | 14 |
| IPSS risk status | ||
| High-risk disease – % of patients | 58 | 64 |
| Intermediate-2 – % of patients | 41 | 35 |
| Previous hydroxyurea use – % of patients | 67 | 57 |
| Median baseline platelet count (range) – ×109/l | 262 (81–984) | 238 (100–887) |
| Median baseline hemoglobin (range) – g/l | 105 (66–170) | 105 (35–173) |
| Median palpable spleen length (range) – cm/spleen volume (range) – cm3 | 16 (0–33)*/2598 (478–7462) | 16 (5–34)/2566 (521–8881) |
| JAK2V617F–positive – % of patients | 73 | 80 |
*
One patient had a baseline spleen length recorded as nonpalpable in error, but had a prior measurement of 16 cm and a baseline spleen volume of 2449.6 cm3. IPSS denotes International Prognosis Scoring System; PET-MF, post–essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; and PPV-MF, post–polycythemia vera myelofibrosis.